Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1146A (Carbomer 980) Nasal Tolerability in Healthy Adults
NCT02832362Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Jul 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in common cold comparing 1146A (Carbomer 980) with Placebo (2 arms). Primary endpoints: Incidences of nasal mucosal changes of ≥ Grade 1B at 8 days, Incidence of moderate or severe mucosal bleeding at 8 days and 1 more. Started Jun 2016; status: completed.
02
Drugs
carbomer
03
Conditions
common cold
Beyond the preview
Go deeper on NCT02832362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832362.